The creation of Enosium Life Science marks the first step in the vision of its founder, Dr. Antoine Amer, to become within five years the European leader in scientific services, addressing the new challenges facing medical and pharmaceutical innovation. Backed by Alpera Partners, a leading private investment firm in France, Enosium Life Science will pursue a targeted acquisition strategy to build a multi-specialist group with European reach, active across the entire healthcare value chain from clinical development to commercialization.
Enosium Life Science was founded by Antoine Amer, a physician and graduate of ESCP and Harvard Business School. With more than 20 years of senior leadership experience in European and international pharmaceutical groups, he brings deep knowledge of the healthcare ecosystem, particularly in business development and the launch of innovative medicines. With the financial support of Alpera Partners, a major investor in high-potential companies, Enosium Life Science has both the ambition and the means to become the European leader in scientific services for the healthcare industries within five years.
A multi-specialist group with European scale, offering a unique life sciences platform
Enosium Life Science will stand out with a unique offering in Europe, combining integrated and complementary services to meet the critical needs of pharmaceutical, biotech, and Medtech companies. Its model will combine cutting-edge local expertise and entrepreneurial agility with the standards and synergies of an international group.
An acquisition strategy built around five core areas of expertise
Drawing on local strengths with an international outlook, Enosium Life Science will focus its targeted acquisitions on five key domains: clinical research (CRO), regulatory affairs, market access and health economics, medical affairs, and marketing. The group will deliver tailored consulting as well as highly specialized and innovative solutions in each area, leveraging a community of European experts to support pharmaceutical companies across the entire lifecycle of their products.
Antoine Amer, Founder and CEO of Enosium Life Science, stated:
“Healthcare industries face growing complexity, high development and commercialization costs, and increasing uncertainty around the introduction of innovations across European markets. Our vision is to bring together the best expertise across Europe to provide them with a unique, comprehensive range of scientific services. This will help them better meet these challenges and accelerate patient access to medical innovations across Europe.”
Basile Paul-Petit, Partner at Alpera Partners in charge of buy-and-build activities, added:
“We are delighted to support Antoine Amer in the creation of Enosium Life Science, which aims within five years to become the reference player in life sciences services in Europe. After the strong growth of Hadrena in leisure, Novavet in veterinary clinics, Otelium in hospitality, and the recent launch of Alfeor in nuclear, Alpera Partners continues to expand its buy-and-build strategy in strategic sectors with a long-term vision.”
About Enosium Life Science
Enosium Life Science is an integrated scientific services group dedicated to healthcare industries in Europe. Covering the full spectrum from strategy to execution, and offering highly specialized services from clinical development to commercialization (clinical research, regulatory affairs, market access, medical affairs, marketing), Enosium Life Science is committed to becoming the partner of choice for healthcare companies in addressing the sector’s challenges.
About Alpera Partners
Alongside bold entrepreneurs, Alpera Partners creates, develops, and scales the leading groups of tomorrow through roll-up platforms.
Each year, Alpera Partners invests more than €80 million in equity to consolidate micro-cap companies in fragmented, high-growth markets and help them grow both organically and through acquisitions. Target markets include healthcare, industry, business services, and real estate.
With this new platform, Alpera Partners has now launched three roll-up platforms: in hospitality (Otelium), nuclear (Alfeor) and healthcare (Enosium Life Science). These complement its established platform in veterinary healthcare (Novavet).
.png)